Average: 5 (1 vote)
Online Exclusive Article

Reasons for Nonadherence to Tamoxifen and Aromatase Inhibitors for the Treatment of Breast Cancer: A Literature Review

Suhila Sawesi
Janet S. Carpenter
Josette Jones
CJON 2014, 18(3), E50-E57 DOI: 10.1188/14.CJON.E50-E57

Despite improved breast cancer survival rates with the use of tamoxifen and aromatase inhibitors, patients remain at risk for cancer recurrence and mortality because of nonadherence to medication. The objective of this review was to identify factors associated with nonadherence among patients with breast cancer. Electronic databases were searched for studies, and potentially relevant studies were retrieved and assessed for eligibility. Potential factors associated with nonadherence were identified, and they included patient-related factors (e.g., patient beliefs and knowledge, fear of adverse effects, forgetfulness, smoking, age, race), therapy-related factors (e.g., duration, side effects, additional prescribed medications, treatment interfering with lifestyle), healthcare system factors (e.g., patient/provider relationships), socioeconomic factors (e.g., medication costs, burden, scheduling problems, religion, marital status), and disease-related factors (e.g., comorbidities, stage of breast cancer). Those findings highlight the need for development of interventions to promote long-term adherence in patients with breast cancer.


Atkins, L., & Fallowfield, L. (2006). Intentional and non-intentional nonadherence to medication amongst breast cancer patients. <i>European Journal of Cancer, 42</i>, 2271-2276. doi:10.1016/j.ejca.2006.03.004

Bhosle, M.J. (2007). <i>Outcomes associated with adjuvant hormonal therapy: Are there any differences between black and white women with primary breast cancer?</i> (Doctoral dissertation). Retrieved from <a target="_blank" href='http://etd.ohiolink.edu/rws_etd/document/get/osu1189093998/inline'>http:...

Bramwell, V.H., Pritchard, K.I., Tu, D., Tonkin, K., Vachhrajani, H., Vandenberg, T.A., … Shepherd, L. (2010). A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12). <i>Annals of Oncology, 21</i>, 283-290. doi:10.1093/annonc/mdp326

Champion, V.L., Skinner, C.S., & Foster, J.L. (2000). The effects of standard care counseling or telephone/in-person counseling on beliefs, knowledge, and behavior related to mammography screening. <i>Oncology Nursing Forum, 27</i>, 1565-1571.

Chlebowski, R.T., & Geller, M.L. (2006). Adherence to endocrine therapy for breast cancer. <i>Oncology, 71</i>, 1-9.

Cramer, J.A., Roy, A., Burrell, A., Fairchild, C.J., Fuldeore, M.J., Ollendorf, D.A., & Wong, P.K. (2008). Medication compliance and persistence: Terminology and definitions. <i>Value in Health, 11</i>, 44-47. doi:10.1111/j.1524-4733.2007.00213.x

Demissie, S., Silliman, R.A., & Lash, T.L. (2001). Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women. <i>Journal of Clinical Oncology, 19</i>, 322-328.

Dezentjé, V.O., van Blijderveen, N.J., Gelderblom, H., Putter, H., van Herk-Sukel, M.P., Casparie, M.K., … Guchelaar, H.J. (2010). Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. <i>Journal of Clinical Oncology, 28</i>, 2423-2429.

Fink, A.K., Gurwitz, J., Rakowski, W., Guadagnoli, E., & Silliman, R.A. (2004). Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. <i>Journal of Clinical Oncology, 22</i>, 3309-3315. doi:10.1200/JCO.2004.11.064

Free, C., Phillips, G., Galli, L., Watson, L., Felix, L., Edwards, P., … Haines, A. (2013). The effectiveness of mobile-health technology-based health behaviour change or disease management interventions for health care consumers: A systematic review. <i>PLoS Medicine, 10</i>, e1001362.

Gotay, C., & Dunn, J. (2011). Adherence to long-term adjuvant hormonal therapy for breast cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research, 11</i>, 709-715.

Grunfeld, E.A., Hunter, M.S., Sikka, P., & Mittal, S. (2005). Adherence beliefs among breast cancer patients taking tamoxifen. <i>Patient Education and Counseling, 59</i>, 97-102. doi:10.1016/j.pec.2004.10.005

Güth, U., Huang, D.J., Schötzau, A., Zanetti-Dällenbach, R., Holzgreve, W., Bitzer, J., & Wight, E. (2008). Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. <i>British Journal of Cancer, 99</i>, 428-433. doi:10.1038/sj.bjc.6604525

Hershman, D.L., Shao, T., Kushi, L.H., Buono, D., Tsai, W.Y., Fehrenbacher, L., … Neugut, A. (2011). Early discontinuation and nonadherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. <i>Breast Cancer Research and Treatment, 126</i>, 529-537. doi:10.1007/s10549-010-1132-4

Huiart, L., Dell'Aniello, S., & Suissa, S. (2011). Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. <i>British Journal of Cancer, 104</i>, 1558-1563. doi:10.1038/bjc.2011.140

Johnston, S.R., & Dowsett, M. (2003). Aromatase inhibitors for breast cancer: Lessons from the laboratory. <i>Nature Reviews. Cancer, 3</i>, 821-831. doi:10.1038/nrc1211

Kahn, K.L., Schneider, E.C., Malin, J.L., Adams, J.L., & Epstein, A.M. (2007). Patient centered experiences in breast cancer: Predicting long-term adherence to tamoxifen use. <i>Medical Care, 45</i>, 431-439. doi:10.1097/01.mlr.0000257193.10760.7f

Kirk, M.C., & Hudis, C.A. (2008). Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. <i>Clinical Breast Cancer, 8</i>, 155-161. doi:10.3816/CBC.2008.n.016

Lash, T.L., Fox, M.P., Westrup, J.L., Fink, A.K., & Silliman, R.A. (2006). Adherence to tamoxifen over the five-year course. <i>Breast Cancer Research and Treatment, 99</i>, 215-220. doi:10.1007/s10549-006-9193-0

Lin, J.H., Zhang, S.M., & Manson, J.E. (2011). Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. <i>Cancer Prevention Research, 4</i>, 1360-1365.

Ma, A.M., Barone, J., Wallis, A.E., Wu, N.J., Garcia, L.B., Estabrook, A., … Tartter, P.I. (2008). Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. <i>American Journal of Surgery, 196</i>, 500-504. doi:10.1016/j.amjsurg.2008.06.027

Mair, F.S., Hiscock, J., & Beaton, S.C. (2008). Understanding factors that inhibit or promote the utilization of telecare in chronic lung disease. <i>Chronic Illness, 4</i>, 110-117.

Maurice, A., Howell, A., Evans, D.G., O'Neil, A.C., & Scobie, S. (2006). Predicting compliance in a breast cancer prevention trial. <i>Breast Journal, 12</i>, 446-450. doi:10.1111/j.1075-122X.2006.00295.x

McCowan, C., Shearer, J., Donnan, P.T., Dewar, J.A., Crilly, M., Thompson, A.M., & Fahey, T.P. (2008). Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. <i>British Journal of Cancer, 99</i>, 1763-1768. doi:10.1038/sj.bjc.6604758

Murphy, T. (200.9, October 27). Experts offer policy recommendations for improving medication adherence. <i>EurekAlert!</i> Retrieved from http://bit.ly/1n24tgm <a target="_blank" href='http://bit.ly/1n24tgm'>http://bit.ly/1n24tgm</a>

Murthy, V., Bharia, G., & Sarin, R. (2002). Tamoxifen non-compliance: Does it matter? <i>Lancet Oncology, 3</i>, 654. doi:10.1016/S1470-2045(02)00895-1

Nekhlyudov, L., Li, L., Ross-Degnan, D., & Wagner, A.K. (2011). Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. <i>Breast Cancer Research and Treatment, 130</i>, 681-689. doi:10.1007/s10549-011-1703-z

Neugut, A.I., Subar, M., Wilde, E.T., Stratton, S., Brouse, C.H., Hillyer, G.C., … Hershman, D.L. (2011). Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. <i>Journal of Clinical Oncology, 29</i>, 2534-2542. doi:10.1200/JCO.2010.33.3179

Oguntola, A.S., Adeoti, M.L., & Akanbi, O.O. (2011). Nonadherence to the use of tamoxifen in the first year by the breast cancer patients in an African population. <i>East and Central African Journal of Surgery, 16</i>(1), 52-56.

Owusu, C., Buist, D.S., Field, T.S., Lash, T.L., Thwin, S.S., Geiger, A.M., … Siliman, R.A. (2008). Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. <i>Journal Of Clinical Oncology, 26</i>, 549-555. doi:10.1200/JCO.2006.10.1022

Partridge, A.H., LaFountain, A., Mayer, E., Taylor, B.S., Winer, E., & Asnis-Alibozek, A. (2008). Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. <i>Journal of Clinical Oncology, 26</i>, 556-562. doi:10.1200/JCO.2007.11.5451

Partridge, A.H., Wang, P.S., Winer, E.P., & Avorn, J. (2003). Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. <i>Journal of Clinical Oncology, 21</i>, 602-606. doi:10.1200/JCO.2003.07.071

Pellegrini, I., Sarradon-Eck, A., Soussan, P.B., Lacour, A.C., Largillier, R., Tallet, A., … Julian-Reynier, C. (2010). Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: Breast cancer patients' point of view. <i>Psycho-Oncology, 19</i>, 472-479. doi:10.1002/pon.1593

Qiang, C.Z., Yamamichi, M., Hausman, V., & Altman, D. (2011). <i>Mobile applications for the health sector.</i> Retrieved from http://bit.ly/1u3I86f <a target="_blank" href='http://bit.ly/1u3I86f'>http://bit.ly/1u3I86f</a>

Sedjo, R.L., & Devine, S. (2011). Predictors of nonadherence to aromatase inhibitors among commercially insured women with breast cancer. <i>Breast Cancer Research and Treatment, 125</i>, 191-200. doi:10.1007/s10549-010-0952-6

Thirumurthy, H., & Lester, R.T. (2012). M-health for health behaviour change in resource-limited settings: Applications to HIV care and beyond. <i>Bulletin of the World Health Organization, 90</i>, 390-392.

van Herk-Sukel, M.P., van de Poll-Franse, L.V., Voogd, A.C., Nieuwenhuijzen, G.A., Coebergh, J.W., & Herings, R.M. (2010). Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis. <i>Breast Cancer Research and Treatment</i>, <i>122</i>, 843-851. doi:10.1007/s10549-009-0724-3

Waterhouse, D.M., Calzone, K.A., Mele, C., & Brenner, D.E. (1993). Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. <i>Journal of Clinical Oncology, 11</i>, 1189-1197.

World Health Organization. (2003). <i>Adherence to long-term therapies: Evidence for action.</i> Retrieved from <a target="_blank" href='http://whqlibdoc.who.int/publications/2003/9241545992.pdf'>http://whqlib...

World Health Organization. (2014). Breast cancer: Prevention and control. Retrieved from <a target="_blank" href='http://www.who.int/cancer/detection/breastcancer/en/index1.html'>http://...

Ziller, V., Kalder, M., Albert, U.S., Holzhauer, W., Ziller, M., Wagner, U., & Hadji, P. (2009). Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. <i>Annals of Oncology, 20</i>, 431-436. doi:10.1093/annonc/mdn646